Eli Lilly and Company — LLY
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $1073.29 | $962.16B | 52.7 | 32.8 | 22.2% | 16.7% | $6.23 0.6% | 40.4 |
Latest Headlines
- · Nvidia Eyes First Breakout Of 2026 — But Resistance Remains
- · Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk
- · Eli Lilly's Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
- · Novo Nordisk to Keep Pursuing Deals to Expand Obesity Portfolio, CEO Says
- · Why Eli Lilly Stock Gained 39.2% In 2025
- · The Bull Case For Revvity (RVTY) Could Change Following Upbeat 2025 Guidance And New Lilly AI Alliance
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $24.5B | $6.2B | $6.47 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $28.3B | $5.6B | $5.85 | 15.4% | -9.9% | -9.6% |
| 2 | 2022-12-31 | $28.5B | $6.2B | $6.57 | 0.8% | 11.9% | 12.3% |
| 3 | 2023-12-31 | $34.1B | $5.2B | $5.82 | 19.6% | -16.1% | -11.4% |
| 4 | 2024-12-31 | $45.0B | $10.6B | $11.76 | 32.0% | 102.1% | 102.1% |
| 5 | TTM 2025-03-31 | $49.0B | $11.1B | $12.31 | 8.8% | 4.9% | 4.7% |
| 6 | Average | 15.3% | 18.6% | 19.6% |
EPS
Forecasts
Y/Y % Change
LLY Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 15.4% | 0.8% | 19.6% | 32.0% | 41.5% | 22.4% | 21.9% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 6 | 6 | |
| EPS Growth (%) | -9.9% | 11.9% | -16.1% | 102.1% | 101.9% | 39.4% | 38.2% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 7 | 7 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | G&A ($) | SG&A ($) | Facilities / D&A ($) | Personnel ($) |
|---|---|---|---|---|---|---|---|
| 2021 | $28.3B | $5.8B | $6.9B | $6.1B | $6.1B | $1.5B | $-289.7M |
| 2022 | $28.5B | $5.1B | $7.2B | $6.1B | $6.1B | $1.5B | $-372.9M |
| 2023 | $34.1B | $5.6B | $9.3B | $6.9B | $6.9B | $1.5B | $-461.9M |
| 2024 | $45.0B | $6.7B | $11.0B | $8.1B | $8.1B | $1.8B | $-461.7M |
| TTM | $59.4B | $8.2B | $12.6B | $9.9B | $9.9B | $1.9B | $-441.8M |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | G&A Change (%) | SG&A Change (%) | Facilities / D&A Change (%) | Personnel Change (%) |
|---|---|---|---|---|---|---|---|
| 2022 | 0.79 | -11.41 | 3.75 | -1.21 | -1.21 | -1.62 | 28.72 |
| 2023 | 19.56 | 8.76 | 29.52 | 14.40 | 14.40 | 0.32 | 23.87 |
| 2024 | 32.00 | 19.74 | 18.01 | 17.16 | 17.16 | 15.67 | -0.04 |
| TTM | 31.92 | 23.10 | 14.26 | 22.30 | 22.30 | 7.33 | -4.31 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $100,923M |
| 1 | Cash | $3,376M |
| 2 | Total Liabilities | $82,574M |
| 3 | Total Debt | $39,904M |
| 4 | Total Equity | $18,273M |
| 5 | Debt to Equity Ratio | 2.18 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $1073.29 | 4.1% | FINVIZ Growth: 46% | Nicks: 7 Finviz: 333 |
Nick's: 0.000 | 16.2 | 52.7 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $20.36 EPS | TTM | $133.40 | -87.6% | $6777.19 | 531.4% |
| $23.85 EPS | 2025 | $156.27 | -85.4% | $7938.90 | 639.7% |
| $33.25 EPS | 2026 | $217.85 | -79.7% | $11067.85 | 931.2% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | 22.23% | 17.67% | 22.01% | 17.39% | 1.53% | 1.45% | 22.30% | 16.81% | 62.4% | 28.2% |
| 3 Years | 22.23% | 17.67% | 22.01% | 17.39% | 1.53% | 1.45% | 22.30% | 16.81% | 62.4% | 28.2% |
| 5 Years | 22.23% | 17.67% | 22.01% | 17.39% | 1.53% | 1.45% | 22.30% | 16.81% | 62.4% | 28.2% |
| 10 Years | 22.23% | 17.67% | 22.01% | 17.39% | 1.53% | 1.45% | 22.30% | 16.81% | 62.4% | 28.2% |